1	Photodynamic	Photodynamic	B-NP	JJ	O	2	NMOD	0
2	therapy	therapy	I-NP	NN	O	15	NMOD	0
3	with	with	B-PP	IN	O	2	NMOD	0
4	verteporfin	verteporfin	B-NP	NN	O	3	PMOD	0
5	for	for	B-PP	IN	O	4	NMOD	0
6	subfoveal	subfoveal	B-NP	JJ	O	8	NMOD	0
7	choroidal	choroidal	I-NP	JJ	O	8	NMOD	0
8	neovascularization	neovascularization	I-NP	NN	O	5	PMOD	3	neovascularization
9	secondary	secondary	B-ADJP	JJ	O	8	NMOD	0
10	to	to	B-PP	TO	O	9	AMOD	0
11	pathologic	pathologic	B-NP	JJ	O	12	NMOD	0
12	myopia	myopia	I-NP	NN	O	10	PMOD	0
13	:	:	O	:	O	2	P	0
14	long-term	long-term	B-NP	JJ	O	15	NMOD	0
15	study	study	I-NP	NN	O	0	ROOT	0
16	.	.	O	.	O	15	P	0

1	PURPOSE	PURPOSE	B-NP	NN	O	0	ROOT	0
2	:	:	O	:	O	1	P	0
3	To	To	B-VP	TO	O	4	VMOD	0
4	assess	assess	I-VP	VB	O	1	NMOD	0
5	the	the	B-NP	DT	O	8	NMOD	0
6	safety	safety	I-NP	NN	O	8	NMOD	0
7	and	and	I-NP	CC	O	8	NMOD	0
8	effectiveness	effectiveness	I-NP	NN	O	4	OBJ	0
9	of	of	B-PP	IN	O	8	NMOD	0
10	photodynamic	photodynamic	B-NP	JJ	O	11	NMOD	0
11	therapy	therapy	I-NP	NN	O	9	PMOD	0
12	(	(	O	(	O	14	DEP	0
13	PDT	PDT	B-NP	NN	O	14	DEP	0
14	)	)	O	)	O	11	NMOD	0
15	with	with	B-PP	IN	O	11	NMOD	0
16	verteporfin	verteporfin	B-NP	NN	O	15	PMOD	0
17	for	for	B-PP	IN	O	16	NMOD	0
18	subfoveal	subfoveal	B-NP	JJ	O	20	NMOD	0
19	choroidal	choroidal	I-NP	JJ	O	20	NMOD	0
20	neovascularization	neovascularization	I-NP	NN	O	17	PMOD	3	neovascularization
21	(	(	O	(	O	23	DEP	0
22	CNV	CNV	B-NP	NN	O	23	DEP	3	CNV
23	)	)	O	)	O	20	NMOD	0
24	secondary	secondary	B-ADJP	JJ	O	20	NMOD	0
25	to	to	B-PP	TO	O	24	AMOD	0
26	pathologic	pathologic	B-NP	JJ	O	27	NMOD	0
27	myopia	myopia	I-NP	NN	O	25	PMOD	0
28	(	(	O	(	O	30	DEP	0
29	PM	PM	B-NP	NN	O	30	DEP	0
30	)	)	O	)	O	27	NMOD	0
31	.	.	O	.	O	4	P	0

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT	0
2	:	:	O	:	O	1	P	0
3	Sixty-two	Sixty-two	B-NP	CD	O	4	NMOD	0
4	patients	patient	I-NP	NNS	O	11	SUB	0
5	(	(	O	(	O	8	DEP	0
6	62	62	B-NP	CD	O	7	NMOD	0
7	eyes	eye	I-NP	NNS	O	8	DEP	0
8	)	)	O	)	O	4	NMOD	0
9	with	with	B-PP	IN	O	4	NMOD	0
10	PM	PM	B-NP	NN	O	9	PMOD	0
11	underwent	undergo	B-VP	VBD	O	1	NMOD	0
12	PDT	PDT	B-NP	NN	O	11	OBJ	19	PDT
13	according	accord	B-PP	VBG	O	11	VMOD	0
14	to	to	B-PP	TO	O	13	PMOD	0
15	the	the	B-NP	DT	O	16	NMOD	0
16	guidelines	guideline	I-NP	NNS	O	14	PMOD	0
17	of	of	B-PP	IN	O	16	NMOD	0
18	the	the	B-NP	DT	O	19	NMOD	0
19	Verteporfin	Verteporfin	I-NP	NNP	O	17	PMOD	0
20	in	in	B-PP	IN	O	19	NMOD	0
21	Photodynamic	Photodynamic	B-NP	NNP	O	23	NMOD	0
22	Therapy	Therapy	I-NP	NNP	O	23	NMOD	0
23	Study	Study	I-NP	NNP	O	20	PMOD	0
24	.	.	O	.	O	1	P	0

1	Clinical	Clinical	B-NP	JJ	O	2	NMOD	0
2	evaluations	evaluation	I-NP	NNS	O	8	SUB	0
3	performed	perform	B-VP	VBN	O	2	NMOD	0
4	at	at	B-PP	IN	O	3	VMOD	0
5	all	all	B-NP	DT	O	7	NMOD	0
6	study	study	I-NP	NN	O	7	NMOD	0
7	visits	visit	I-NP	NNS	O	4	PMOD	0
8	included	include	B-VP	VBD	O	0	ROOT	0
9	measurement	measurement	B-NP	NN	O	8	OBJ	0
10	of	of	B-PP	IN	O	9	NMOD	0
11	best-corrected	best-corrected	B-NP	JJ	O	14	NMOD	0
12	Snellen	Snellen	I-NP	NN	O	14	NMOD	0
13	visual	visual	I-NP	JJ	O	14	NMOD	0
14	acuity	acuity	I-NP	NN	O	22	NMOD	0
15	,	,	O	,	O	22	P	0
16	slit-lamp	slit-lamp	B-NP	JJ	O	17	NMOD	0
17	biomicroscopy	biomicroscopy	I-NP	NN	O	22	NMOD	0
18	,	,	O	,	O	22	P	0
19	and	and	O	CC	O	22	NMOD	0
20	fundus	fundus	B-NP	NN	O	22	NMOD	0
21	fluorescein	fluorescein	I-NP	NN	O	22	NMOD	0
22	angiography	angiography	I-NP	NN	O	10	PMOD	19	angiography
23	.	.	O	.	O	8	P	0

1	Patients	Patient	B-NP	NNS	O	2	SUB	0
2	were	be	B-VP	VBD	O	0	ROOT	0
3	followed	follow	I-VP	VBN	O	2	VC	0
4	up	up	B-PRT	RP	O	3	VMOD	0
5	at	at	B-PP	IN	O	3	VMOD	0
6	1	1	B-NP	CD	O	7	NMOD	0
7	month	month	I-NP	NN	O	10	NMOD	0
8	and	and	O	CC	O	10	NMOD	0
9	3	3	B-NP	CD	O	10	NMOD	0
10	months	month	I-NP	NNS	O	5	PMOD	0
11	after	after	B-PP	IN	O	3	VMOD	0
12	treatment	treatment	B-NP	NN	O	11	PMOD	19	treatment
13	and	and	O	CC	O	3	VMOD	0
14	thereafter	thereafter	B-ADVP	RB	O	3	VMOD	0
15	at	at	B-PP	IN	O	14	PMOD	0
16	3-month	3-month	B-NP	JJ	O	17	NMOD	0
17	intervals	interval	I-NP	NNS	O	15	PMOD	0
18	.	.	O	.	O	2	P	0

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT	0
2	:	:	O	:	O	1	P	0
3	The	The	B-NP	DT	O	6	NMOD	0
4	final	final	I-NP	JJ	O	6	NMOD	0
5	visual	visual	I-NP	JJ	O	6	NMOD	0
6	acuity	acuity	I-NP	NN	O	44	SUB	0
7	of	of	B-PP	IN	O	6	NMOD	0
8	the	the	B-NP	DT	O	10	NMOD	0
9	study	study	I-NP	NN	O	10	NMOD	0
10	patients	patient	I-NP	NNS	O	7	PMOD	0
11	,	,	O	,	O	6	P	0
12	after	after	B-PP	IN	O	6	NMOD	0
13	a	a	B-NP	DT	O	15	NMOD	0
14	median	median	I-NP	JJ	O	15	NMOD	0
15	follow-up	follow-up	I-NP	NN	O	12	PMOD	0
16	of	of	B-PP	IN	O	15	NMOD	0
17	31	31	B-NP	CD	O	18	NMOD	0
18	months	month	I-NP	NNS	O	16	PMOD	0
19	,	,	O	,	O	6	P	0
20	improved	improve	B-VP	VBN	O	6	NMOD	0
21	by	by	B-PP	IN	O	20	VMOD	0
22	greater	great	B-ADJP	JJR	O	21	PMOD	0
23	than	than	B-PP	IN	O	22	AMOD	0
24	or=1	or=1	B-NP	NN	B-cell_line	26	NMOD	0
25	Snellen	Snellen	I-NP	NN	I-cell_line	26	NMOD	0
26	lines	line	I-NP	NNS	I-cell_line	23	PMOD	0
27	in	in	B-PP	IN	O	26	NMOD	0
28	8	8	B-NP	CD	O	29	NMOD	0
29	patients	patient	I-NP	NNS	O	27	PMOD	0
30	(	(	O	(	O	33	DEP	0
31	13	13	B-NP	CD	O	32	NMOD	0
32	%	%	I-NP	NN	O	33	DEP	0
33	)	)	O	)	O	29	NMOD	0
34	,	,	O	,	O	6	P	0
35	deteriorated	deteriorate	B-VP	VBN	O	6	NMOD	0
36	in	in	B-PP	IN	O	35	VMOD	0
37	20	20	B-NP	CD	O	36	PMOD	0
38	(	(	O	(	O	41	DEP	0
39	32	32	B-NP	CD	O	40	NMOD	0
40	%	%	I-NP	NN	O	41	DEP	0
41	)	)	O	)	O	37	NMOD	0
42	,	,	O	,	O	6	P	0
43	and	and	O	CC	O	6	VMOD	0
44	remained	remain	B-VP	VBD	O	1	NMOD	0
45	stable	stable	B-ADJP	JJ	O	44	PRD	0
46	in	in	B-PP	IN	O	45	AMOD	0
47	34	34	B-NP	CD	O	46	PMOD	0
48	(	(	O	(	O	51	DEP	0
49	55	55	B-NP	CD	O	50	NMOD	0
50	%	%	I-NP	NN	O	51	DEP	0
51	)	)	O	)	O	47	NMOD	0
52	.	.	O	.	O	1	P	0

1	The	The	B-NP	DT	O	4	NMOD	0
2	baseline	baseline	I-NP	NN	O	4	NMOD	0
3	visual	visual	I-NP	JJ	O	4	NMOD	0
4	acuity	acuity	I-NP	NN	O	5	SUB	0
5	was	be	B-VP	VBD	O	0	ROOT	0
6	similar	similar	B-ADJP	JJ	O	5	PRD	0
7	in	in	B-PP	IN	O	6	AMOD	0
8	the	the	B-NP	DT	O	11	NMOD	0
9	various	various	I-NP	JJ	O	11	NMOD	0
10	study	study	I-NP	NN	O	11	NMOD	0
11	groups	group	I-NP	NNS	O	7	PMOD	0
12	.	.	O	.	O	5	P	0

1	The	The	B-NP	DT	O	5	NMOD	0
2	final	final	I-NP	JJ	O	5	NMOD	0
3	mean	mean	I-NP	JJ	O	5	NMOD	0
4	visual	visual	I-NP	JJ	O	5	NMOD	0
5	acuity	acuity	I-NP	NN	O	17	SUB	0
6	in	in	B-PP	IN	O	5	NMOD	0
7	group	group	B-NP	NN	O	8	NMOD	0
8	A	A	I-NP	NN	O	6	PMOD	0
9	(	(	O	(	O	16	DEP	0
10	55	55	B-NP	CD	O	11	NMOD	0
11	years	year	I-NP	NNS	O	16	DEP	0
12	of	of	B-PP	IN	O	11	NMOD	0
13	age	age	B-NP	NN	O	15	NMOD	0
14	or	or	O	CC	O	15	NMOD	0
15	younger	younger	B-NP	NN	O	12	PMOD	0
16	)	)	O	)	O	5	NMOD	0
17	was	be	B-VP	VBD	O	0	ROOT	0
18	20/80	20/80	B-NP	CD	O	17	PRD	0
19	and	and	O	CC	O	18	NMOD	0
20	significantly	significantly	O	RB	O	19	PRD	0
21	(	(	O	(	O	23	DEP	0
22	P=0.006	P=0.006	B-NP	NN	O	23	DEP	0
23	)	)	O	)	O	20	AMOD	0
24	better	well	B-ADVP	RBR	O	20	AMOD	0
25	than	than	B-PP	IN	O	24	AMOD	0
26	that	that	B-NP	DT	O	25	PMOD	0
27	(	(	O	(	O	29	DEP	0
28	20/138	20/138	B-NP	CD	O	29	DEP	0
29	)	)	O	)	O	26	NMOD	0
30	in	in	B-PP	IN	O	24	AMOD	0
31	group	group	B-NP	NN	O	32	NMOD	0
32	B	B	I-NP	NN	O	30	PMOD	0
33	(	(	O	(	O	40	DEP	0
34	older	old	B-ADJP	JJR	O	40	DEP	0
35	than	than	B-PP	IN	O	34	AMOD	0
36	55	55	B-NP	CD	O	37	NMOD	0
37	years	year	I-NP	NNS	O	35	SBAR	0
38	of	of	B-PP	IN	O	37	NMOD	0
39	age	age	B-NP	NN	O	38	PMOD	0
40	)	)	O	)	O	32	NMOD	0
41	.	.	O	.	O	17	P	0

1	The	The	B-NP	DT	O	5	NMOD	0
2	mean	mean	I-NP	JJ	O	5	NMOD	0
3	final	final	I-NP	JJ	O	5	NMOD	0
4	visual	visual	I-NP	JJ	O	5	NMOD	0
5	acuity	acuity	I-NP	NN	O	20	SUB	0
6	in	in	B-PP	IN	O	5	NMOD	0
7	eyes	eye	B-NP	NNS	O	6	PMOD	0
8	with	with	B-PP	IN	O	7	NMOD	0
9	higher	high	B-NP	JJR	O	11	NMOD	0
10	refractive	refractive	I-NP	JJ	O	11	NMOD	0
11	error	error	I-NP	NN	O	8	PMOD	0
12	at	at	B-PP	IN	O	11	NMOD	0
13	baseline	baseline	B-NP	NN	O	12	PMOD	0
14	(	(	O	(	O	19	DEP	0
15	greater	great	B-NP	JJR	O	18	NMOD	0
16	than	than	I-NP	IN	O	18	NMOD	0
17	-17	-17	I-NP	CD	O	16	AMOD	0
18	diopters	diopter	I-NP	NNS	O	19	DEP	0
19	)	)	O	)	O	11	NMOD	0
20	was	be	B-VP	VBD	O	0	ROOT	0
21	significantly	significantly	B-ADJP	RB	O	22	AMOD	0
22	better	good	I-ADJP	JJR	O	20	PRD	0
23	(	(	O	(	O	25	DEP	0
24	P=0.014	P=0.014	B-NP	NN	O	25	DEP	0
25	)	)	O	)	O	22	AMOD	0
26	than	than	B-PP	IN	O	22	AMOD	0
27	that	that	B-NP	DT	O	26	PMOD	0
28	in	in	B-PP	IN	O	27	NMOD	0
29	eyes	eye	B-NP	NNS	O	28	PMOD	0
30	with	with	B-PP	IN	O	29	NMOD	0
31	lower	low	B-NP	JJR	O	32	AMOD	0
32	refractive	refractive	I-NP	JJ	O	33	NMOD	0
33	error	error	I-NP	NN	O	30	PMOD	0
34	(	(	O	(	O	39	DEP	0
35	-6	-6	B-NP	CD	O	37	AMOD	0
36	to	to	B-NP	TO	O	37	AMOD	0
37	-10	-10	I-NP	CD	O	38	NMOD	0
38	diopters	diopter	I-NP	NNS	O	39	DEP	0
39	)	)	O	)	O	33	NMOD	0
40	.	.	O	.	O	20	P	0

1	CNV	CNV	B-NP	NN	O	2	NMOD	3	CNV
2	size	size	I-NP	NN	O	3	SUB	0
3	did	do	B-VP	VBD	O	0	ROOT	0
4	not	not	I-VP	RB	O	3	VMOD	0
5	affect	affect	I-VP	VB	O	3	VC	0
6	visual	visual	B-NP	JJ	O	7	NMOD	0
7	outcomes	outcome	I-NP	NNS	O	5	OBJ	0
8	.	.	O	.	O	3	P	0

1	CONCLUSION	CONCLUSION	B-NP	NN	O	4	VMOD	0
2	:	:	O	:	O	4	P	0
3	PDT	PDT	B-NP	NN	O	4	SUB	19	PDT
4	preserves	preserve	B-VP	VBZ	O	0	ROOT	0
5	vision	vision	B-NP	NN	O	4	OBJ	0
6	in	in	B-PP	IN	O	4	VMOD	0
7	patients	patient	B-NP	NNS	O	6	PMOD	0
8	with	with	B-PP	IN	O	7	NMOD	0
9	CNV	CNV	B-NP	NN	O	8	PMOD	3	CNV
10	associated	associate	B-VP	VBN	O	9	NMOD	0
11	with	with	B-PP	IN	O	10	VMOD	0
12	PM	PM	B-NP	NN	O	11	PMOD	0
13	.	.	O	.	O	4	P	0

1	Younger	Young	B-NP	JJR	O	2	NMOD	0
2	patients	patient	I-NP	NNS	O	4	NMOD	0
3	and	and	I-NP	CC	O	4	NMOD	0
4	eyes	eye	I-NP	NNS	O	9	SUB	0
5	with	with	B-PP	IN	O	4	NMOD	0
6	higher	high	B-NP	JJR	O	8	NMOD	0
7	refractive	refractive	I-NP	JJ	O	8	NMOD	0
8	error	error	I-NP	NN	O	5	PMOD	0
9	appear	appear	B-VP	VBP	O	0	ROOT	0
10	more	more	B-ADJP	RBR	O	11	AMOD	0
11	likely	likely	I-ADJP	JJ	O	9	PRD	0
12	to	to	B-VP	TO	O	13	VMOD	0
13	benefit	benefit	I-VP	VB	O	11	AMOD	0
14	from	from	B-PP	IN	O	13	VMOD	0
15	PDT	PDT	B-NP	NN	O	14	PMOD	19	PDT
16	with	with	B-PP	IN	O	15	NMOD	0
17	verteporfin	verteporfin	B-NP	NN	O	16	PMOD	0
18	.	.	O	.	O	9	P	0

